Drawing on our executive search practice, we put this together to give employers a grounded, practical view they can act on. The Chief Medical Officer in a pharmaceutical company holds an unusual combination of responsibilities: scientific and clinical leadership, regulatory engagement, safety judgment, and increasingly a commercial-facing role in shaping evidence and medical strategy. Recruiting one well means being clear about which version of the CMO role you actually need, because the title covers several substantially different jobs.
Key Takeaways
- The CMO title covers several genuinely different roles in pharma.
- Clarify whether you need clinical development, medical affairs, or safety leadership.
- Therapeutic area experience matters more than general pharma seniority.
- Safety and benefit-risk judgment is a non-delegable part of the role.
- Match the CMO to your stage: pre-clinical, development, or commercial.
Decide Which CMO You Need
In some companies the CMO leads clinical development, designing and running trials that support approval. In others the role is centred on medical affairs, engaging with the medical community, generating and communicating evidence post-approval. In others still it is weighted toward pharmacovigilance and safety, or toward being the senior clinical voice to regulators and the board. These require different backgrounds, and a candidate excellent in one may be unsuited to another. Before recruiting, decide explicitly which weighting you need, because the most common cause of a failed CMO hire is a mismatch between the role as advertised and the role as it actually is.
Therapeutic Area Depth Matters
In pharmaceutical medicine, therapeutic area expertise is not interchangeable. An oncology CMO and a CMO from immunology or neurology bring different understandings of trial design, endpoints, regulatory precedent, competitive landscape, and the physician community. For companies with a concentrated pipeline, therapeutic depth in that area usually outweighs broader but shallower pharmaceutical seniority, because the judgment calls the CMO makes, on endpoints, on trial populations, on benefit-risk, are deeply area-specific. Weight this accordingly rather than treating any experienced pharma physician as fungible.
Safety and Benefit-Risk Judgment
Whatever the role’s weighting, the CMO carries responsibility for safety and benefit-risk judgment that cannot be delegated away. This means assessing not just scientific and clinical capability but judgment and integrity under pressure: how the candidate has handled emerging safety signals, disagreements with commercial colleagues about data interpretation, and decisions about whether to continue or stop a programme. Ask directly about these situations. A CMO who cannot describe a moment where they held a difficult clinical line is either inexperienced or has not been in a position where it mattered.
Match to Company Stage
A pre-clinical or early development biotech needs a CMO who can design a development programme and engage regulators from a standing start, often hands-on and with limited support. A late-stage or commercial company needs someone who can lead a larger organisation, support launch and lifecycle evidence, and work closely with commercial. These are different jobs requiring different people, and a distinguished CMO from a large pharmaceutical company may struggle in a lean biotech where they must personally write protocols and lack a supporting infrastructure. Match to stage as carefully as to therapeutic area.
What This Looks Like in Practice
A pharma company recruiting a CMO first decides explicitly which weighting the role carries, clinical development, medical affairs, safety, or a combination, weights therapeutic area depth heavily for a concentrated pipeline, probes safety and benefit-risk judgment through specific past situations, and matches the candidate’s background to the company’s development stage.
The Mistake Employers Keep Making
The most common mistake is recruiting for the title rather than the role, producing a brief that describes a CMO in general terms and attracting candidates whose experience is centred on a different version of the job. A medical affairs leader hired into a clinical development-weighted role, or a large-pharma CMO hired into a lean biotech, may be excellent and still fail. The company mistakes seniority in the title for fit to the actual work.
Different CMO Roles Under One Title
| Weighting | Core Responsibility | Best Background |
|---|---|---|
| Clinical development | Designing and running trials | Development physician, relevant TA |
| Medical affairs | Evidence generation and medical engagement | Medical affairs leadership |
| Safety and pharmacovigilance | Benefit-risk and signal management | Safety physician background |
| Board and regulatory voice | Senior clinical representation | Broad, regulator-facing experience |
The Bottom Line
The CMO title covers several substantially different jobs, so decide explicitly which weighting your company needs, weight therapeutic area depth heavily, probe safety and benefit-risk judgment directly, and match the candidate to your development stage rather than recruiting for seniority in the title. Get this right and the hire becomes a genuine multiplier; get it wrong and no amount of general talent compensates.
Related Reading
For more, see Building an Executive Team for a Pre-Commercial Biotech, Recruiting for Rare Disease and Orphan Drug Companies, What Makes a Great VP of Market Access in Pharma.
Frequently Asked Questions
- Q: What does a pharma CMO actually do?
- A: It varies; the role may centre on clinical development, medical affairs, safety and pharmacovigilance, or serving as the senior clinical voice to regulators and the board.
- Q: How much does therapeutic area experience matter?
- A: Considerably for concentrated pipelines, since trial design, endpoints, regulatory precedent, and physician communities differ substantially between therapeutic areas.
- Q: What should I assess beyond scientific capability?
- A: Safety and benefit-risk judgment under pressure, including how the candidate handled emerging safety signals or disagreements with commercial colleagues about data interpretation.
- Q: Does company stage change the profile?
- A: Yes; an early biotech needs a hands-on CMO who can build a programme from a standing start, while a commercial company needs someone who can lead a larger organisation.
- Q: What is the most common CMO hiring mistake?
- A: Recruiting for the title rather than the specific role weighting, attracting candidates whose experience centres on a different version of the job.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
